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Abstract: 
In spite of genome sequences of both human and N. gonorrhoeae in hand, vaccine for gonorrhea is yet not available. Due to availability of several host 
and pathogen genomes and numerous tools for in silico prediction of effective B-cell and T-cell epitopes; recent trend of vaccine designing has been 
shifted to peptide or epitope based vaccines that are more specific, safe, and easy to produce. In order to design and develop such a peptide vaccine 
against the pathogen, we adopted a novel computational approach based on sequence, structure, QSAR, and simulation methods along with fold level 
analysis to predict potential antigenic B-cell epitope derived T-cell epitopes from four vaccine targets of N. gonorrhoeae previously identified by us [Barh 
and Kumar (2009) In Silico Biology 9, 1-7]. Four epitopes, one from each protein, have been designed in such a way that each epitope is highly likely to 
bind maximum number of HLA molecules (comprising of both the MHC-I and II) and interacts with most frequent HLA alleles (A*0201, A*0204, 
B*2705, DRB1*0101, and DRB1*0401) in human population. Therefore our selected epitopes are highly potential to induce both the B-cell and T-cell 
mediated immune responses. Of course, these selected epitopes require further experimental validation. 
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Background: 
The disease, gonorrhea is a wide spread sexually transmitted disease 
caused by infection and transmission of N. gonorrhoeae. It is a drastic 
disease responsible for developing acquired immune deficiency syndrome 
(AIDS). Several attempts have been made for the development of vaccines 
for drastic diseases like AIDS [1] and flue viruses [2]. Vaccine 
development for gonorrhea, an age old disease is not in sight. However, 
several vaccine targets viz. protein-I B (porB) [3], opacity protein (opa), 
lipo-oligosaccharides, protein-I, lactoferrin-1 and -2 (lbpl, lbp2), 
Immunoglobulin A1 (IgA1) proteases [4], phospholipase A (pldA) [5], 
transferrin-binding protein -A and -B (tbpA and tbpB) [6-8], 2C7 
oligosaccharide [9]  have been identified for N. gonorrhoeae and few of 
them viz. pili (US4443431), T-cell stimulating protein-A and -B (tspA and 
tspB) (US6861507) have been patented. However, the problem still 
remains unsolved. Candidate vaccines identified and tested from these 
targets are only partially successful perhaps due to wide adoptability of the 
gonococcus, lack of proper animal models for the disease, cell lines to 
produce the vaccine, and inadequate immune response of used epitopes 
derived from these target proteins. 
 
Secreted and surface proteins of any given pathogen are mostly antigenic 
and are responsible for pathogenicity [10]. Hence, these are good vaccine 
candidates. B-cell epitopes are parts of proteins that are antigenic and 
therefore are recognized by the antibodies. Identification of B-cell epitopes 
is useful development of diagnostic tests and can be employed as the first 
step in vaccine designing [11]. Similarly, effective immune response 
depends on specificity and diversity of the antigen binding to the  human 
leukocyte antigen (HLA) alleles [12] class I (recognizes CD8+ T-cells) and 
class II (recognizes CD4+ T-cells) [13, 14]. The HLA molecules are highly 
polymorphic and according to IMGT/HLA Database 
(http://www.ebi.ac.uk/imgt/hla/stats.html), there are 4,633 HLA alleles 
(Class-I =3,411 and Class-II = 1,222) [15]. Among these, DRB1*0101, 
DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1801, DRB1*1101 and 
DRB1*1501 of Class-II HLA alleles are most frequent (20-50%) [16]. 
Evidences are that gonococcal infection decreases the CD4+ and CD8+ T-
cell counts [17, 18] and Pili proteins modulate initial CD4+ T-cell 
proliferation and regulatory T-cell activation thereby may evoke immune 
responses [19]. Therefore both these T-cells mediated immunities should 
be considered in designing peptide vaccines against N. gonorrhoeae. A list 
of previously reported T-epitopes is given in Table 1 (see supplementary 
material). 
 
Compared to the conventional vaccines, peptide or epitope based vaccines 
are easy to produce, more specific, and also safe. The advent of human 
genome project, sequencing and functional annotation of several 
pathogenic bacteria has boosted peptide based vaccine designing. Efficacy 
of computational prediction of effective B-cell and T-cell epitopes forms 
pathogenic genome as the key success to develop such vaccines. It  is 
recommended to get an overview of various computational approaches in 
this regard [20].   
 
Previously, we have reported several membrane associated essential 
proteins of the gonococcus using computational approaches that can be 
used in designing new vaccine (s) against the pathogen [21] In the present 
study, four such membrane associated essential gonococcal proteins are 
explored for designing peptide vaccine (s) using a novel in silico strategy 
combined with simulation and fold level verification to identify best 
possible and most effective epitopes that can produce both the B-cell and 
T-cell mediated immunity.  
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Methodology: 
Prediction of antigenic B-cell epitopes:  
Four essential membrane proteins namely D-alanine--D-alanine ligase 
(ddl), Sulfate transport permease protein C (cysW), Competence 
lipoprotein (comL), and Type IV pilin protein (pilV) of N. 
gonorrhoeae virulent  strain  FA 1090 earlier identified as best vaccine 
candidates [21] were selected for the current study and a novel approach of 
epitope designing was adopted where an epitope should produce both the 
B-cell and T-cell mediated immunity.  
 
The complete amino acid sequence of each protein was retrieved from 
Swiss-Prot protein database (http://us.expasy.org/sprot) and analyzed using 
VaxiJen v2.0 antigen prediction server [22].  The  default parameters 
(threshold=0.4, ACC out put) were used against bacterial species to check 
the antigenicity of each full length protein. Proteins having antigenic score 
>0.5 were selected. Each selected full length amino acid sequence was then 
subjected to transmembrane topology analysis using TMHMM v0.2 
prediction server [23] in order to identify exo-membrane (surface exposed) 
amino acid sequences of each protein.  
 
For prediction of B-cell epitopes, each full length protein sequence was 
subjected to BCPreds analysis [24] and all predicted B-cell epitopes (20 
mers) having a BCPreds cutoff score >0.8 were selected. Selected B-cell 
epitopes were then subsequently checked for membrane topology by 
comparing with TMHMM results for exo-membrane amino acid 
sequences. Surface exposed B-cell epitope sequences having the cutoff 
value for BCPreds (>0.8) were selected and further analyzed using VaxiJen 
(threshold=0.4, ACC out put) to check the antigenicity. Finally 2-3 
epitopes with top VaxiJen scores were selected for use in prediction of T-
cell epitopes. 
 
Prediction of T-cell epitopes from B-cell epitopes: 
T-cell epitopes were predicted from the selected B-cell epitopes. Both the 
sequence based and structure based QSAR simulation approaches were 
taken into account to predict T-cell epitopes and two screening steps were 
adopted. In the first screening, the selection criteria were: i) the sequence 
should bind to both the MHC class-I and class-II molecules and minimum 
number of total interacting MHC molecules should be >15, ii) the 
sequence must interact with HLA-DRB1*0101 of MHC class-II, and iii) 
should be antigenic based on VaxiJen score. Propred-1 (47 MHC Class-I 
alleles) [25] and Propred (51 MHC Class-II alleles) [26] servers that utilize 
amino acid position coefficients inferred from literature employing linear 
prediction model [27], were used to identify common epitopes that bind to 
both the MHC class molecules as well as to count total numbers of 
interacting MHC alleles. For QSAR simulation approach, the half maximal 
(50%) inhibitory concentration (IC50) and antigenicity of common epitopes 
predicted by Propred-1 and Propred was calculated using MHCPred v.2 
[28] server (selecting DRB1*0101) and VaxiJen, respectively. Epitopes 
with highest antigenicity and those bind more than 15 MHC molecules 
comprising of both the MHC class I and II alleles and less than 100 nM 
IC50 scores for DRB1*0101 were selected. The second screening was 
based on structure and QSAR simulation methods using T-Epitope 
Designer (http://www.bioinformation.net/ted/) [29] and MHCPred, 
respectively. T-epitope Designer predicts HLA-peptide binding based on 
virtual binding pockets using X-ray crystal structures of HLA-peptide 
complexes followed by calculation of peptide binding to binding pockets. 
The server can screen peptides for >1000 HLA alleles. In the second 
screening, the criteria were: i) binding prediction with large number of 
HLA alleles (>1000), ii) the peptide should bind > 75% of total HLA 
molecules, iii) must bind with high scores to A*0201, A*0204, and 
B*2705, and iv) must bind to DRB1*0101 and DRB1*0401. T-epitope 
Designer was used for criteria i), ii), and iii) and MHCPred was used for 
selection of DRB1*0101 and DRB1*0401 binding peptides. The final list 
of epitopes was made with non overlapping peptide sequences that pass 
these above mentioned criteria and VaxiJen and IC50 scores. Selected 
epitopes were further analyzed for fold level topology.  
 
Epitope analysis: 
Homology modeling for each full length protein was carried out using 
Phyre version 2.0 Web-server [30] and best models were selected based on 
super families and E-values of templates. The 3D folding and clusters of 
epitopes in folded protein were analyzed to confirm the exo-membrane 
topology of these epitopes using Pepitope server [31]. Pepitope was fed 
with Phyre derived 3D structure of each protein and all identified epitopes 
from the same protein to analyze the linear alignment of epitopes on the 
corresponding protein and to determine the epitope clusters and exo-
membrane position of epitopes in the folded proteins. The detailed method 
has been represented in Figure. 1.  
 
Results: 
Antigenicity and topology of selected proteins  
VaxiJen analysis of exo-membrane full length proteins selected for this 
study exhibited various degree of antigenicity ranging from 0.3986 to 
0.6091 (Table 2, column 1 see supplementary material).  Out of the four 
essential membrane proteins, cysW showed highest antigenicity (0.6091). 
Although comL exhibited the lowest score (0.3986) and predicted to be 
non-antigenic by VaxiJen, it was also considered for further analysis. The 
basic criterion of a good epitope is that it must be exposed to cell outside.   
The transmembrane topology analyses of these proteins were done using 
TMHMM and the result revealed that ddl (1- 304 amino acids) and comL 
(1- 267 amino acids) are fully exposed to outside of the membrane. The 
exo-membrane amino acid sequences of cysW are 42 – 66 and 129 – 137, 
and for pilV, the sequence is 30 - 129 (Table 2, column 6) (see 
supplementary material).  
 
Antigenic B-cell epitopes: 
A peptide should be hydrophilic and produce both the B-cell and T-cell 
mediated immunity for becoming a good vaccine candidate [26]. Therefore 
to identify such epitopes, full length proteins were first subjected to B-cell 
epitope prediction using BCpreds and all B-cell epitopes were listed from 
each protein (Table 3 see supplementary material).  Best epitopes were 
selected based on the criteria as mentioned in methods.  In general, 
epitopes having BCpreds and VaxiJen cutoff values respectively >0.8 and 
>0.4 were selected except epitope from cysW where only one 20 mers 
epitope was found exposed to cell out side that has the BCpred and 
VaxiJen scores respectively 0.056 and 0.6316 (Tables 3 see 
supplementary material). Therefore, two epitopes each from ddl, comL, 
and pilV and one from cysW were finally selected for further analysis 
(Table 3 see supplementary material). 
 
B-cell epitopes derived T-cell epitopes: 
Each selected B-cell epitope was analyzed for identification of T-cell 
epitopes within the B-cell epitope sequence. For the first level screening, 
Propred-I (47 MHC Class-I alleles), Propred (51 MHC Class-II alleles), 
and MHCPred (DRB1*0101 allele) were used to identify common T-cell 
epitopes that share B-cell epitope sequence, can interact with both the 
MHC classes with highest number, and specifically interact with 
DRB1*0101 (as the DRB1*0101 is commonest bound allele, therefore the 
interaction epitope should produce better antigenic response) [32] (Table 
4). At the second level of screening, identified peptides in the first screen 
were used to predict their binding abilities to >1000 MHC alleles using T-
Epitope Designer and epitopes that bind to >75% alleles were selected 
(Table 5). Similarly, as A*0201, A*0204, and B*2705 alleles are mostly 
used in various prediction methods [20], we set the cut off that selected 
peptides must bind to these three HLA molecules and T-epitope Designer 
was also used for this purpose (Table 5 see supplementary material). 
Since the frequency of DRB1*0101 and DRB1*0401 alleles of MHC 
class-II is 20-50% [16], we selected T-epitopes that interact with these two 
HLA molecules using MHCPred as described in methods (Table 6 see 
supplementary material). The final list of epitopes was made with non 
overlapping peptide sequences that confirm the above mentioned criteria 
and VaxiJen and IC50 scores (Table 6 see supplementary material). 
Finally, one epitope from each ddl, comL, cysW, and pilV are found to be 
prospective candidates for vaccine design (Table 6, in bold see 
supplementary material). Selected epitopes were further analyzed for 
fold level topology. 
 
Clusters and folding of epitopes: 
There is every possibility of the identified epitopes getting folded inside 
the tertiary structure of the corresponding protein. Therefore, a fold level 
analysis of all identified epitopes was carried out to determine the position 
of epitopes in folded proteins and to confirm their exo-membrane    
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topology. Homology based 3D structures of all four proteins were carried 
out using Phyre server as described under Methods. The Table 7 (see 
supplementary material) represents the summary of Phyre results. 
Analysis of the epitope clusters and positions of epitopes with in the folded 
protein by Pepitope showed that identified all epitopes are situated within 
clusters having acceptable scores, located at the surface of the 
corresponding protein, and exposed to cell out side (Table 4 see 
supplementary material, bold highlighted in last column, and Figure 2). 
Therefore, these results confirmed the suitability of all identified epitopes 
as prospective vaccine candidates. 
 
 
Figure-1: Flow chart of the overall epitope designing methodology employed in this study    
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Figure-2: Fold level characterization of cluster and topoloty of best epitopes using Pepitope (in white). Cluster numbers are also represented. A) ddl, B) 
cysW, C) ComL, and D) pilV. 
 
Discussion: 
Bioinformatics approaches have been successfully used for identification 
of vaccine candidates in several pathogenic bacteria viz. Bacillus anthracis 
[33], Helicobacter pylori [34] and computer assisted epitope designing and 
peptide vaccine have been reported for many bacterial and viral pathogens 
including HIV [35], malaria [36]. In the present study, various 
bioinformatics tools have been used to identify and characterize potential 
epitopes from four vaccine targets of N. gonorrhoeae that might be 
effective to produce both the B-cell and T-cell mediated immunity.  The 
identified epitopes are highly expected to bind both the class of MHC 
molecules specifically, A*0201, A*0204, B*2705, DRB1*0101, and 
DRB1*0401, that are most frequent MHC alleles in human population.  
 
VaxiJen  [22] that predicts antigenicity based on auto cross covariance 
(ACC) transformation of protein sequences into uniform vectors of 
principal amino acid properties with 82% accuracy, 91% sensitivity, and 
72% specificity  for bacterial species based on leave-one-out cross-
validation (LOO-CV) was used in this study to identify antigenicity of 
proteins and peptides. Strategically, B-cell epitope identification can be 
adopted as first step in vaccine designing [11] and BCpreds [24] that uses a 
novel method of subsequence kernel was used to predict linear B-cell 
epitopes from each protein. A good peptide vaccine must be exposed to 
cell out side and to predict the exo-membrane topology of amino acid 
sequences, TMHMM v0.2 prediction server [23] was used. In silico 
quantitative structure-activity relationship (QSAR) [37] based T-cell 
epitopes have been reported recently. MHCPred  [28]  that uses  additive 
method  for binding affinity prediction of MHC molecules and the 
Transporter Associated with Processing (TAP) generates allele specific 
QSAR models using partial least squares (PLS) were used in the present 
study. MHCPred  has been used to identify T-cell epitopes for malarial 
merozoite surface protein-1 [36] and a combination of SYFPEITHI, 
NetMHC and MHCPred has been used for Epstein-Barr virus latent 
membrane protein-2A [38].  Similarly, Propred and Propred-1 have been 
also used for the same purpose and these two server based T-cell epitope 
prediction have recently been reported for development of dengue virus 
vaccine  [39]. To select MHC molecule binding peptides from a large 
number of MHC pool, we have also used T-Epitope Designer that predicts 
HLA-peptide binding calculated from structure based virtual binding 
pockets of HLA-peptide complexes [29]. We have also used two screening 
strategies to select T-epitopes in this study. The identified epitopes have 
been further characterized with Peptiope server [31] that predicts 
discontinuous epitopes based on a set of peptides that were affinity-
selected against a monoclonal
 antibody or peptides extracted from a phage 
display library. It also aligns a linear peptide sequence onto a 3D protein 
structure. Therefore, pepitope is helpful to identify epitopes based on 
physicochemical
 properties and spatial or fold level organization. 
 
Considering the highest number of MHC allele binding epitope at the first 
level of T-epitope screening, “LNSSNYTRA” from comL cluster-I (Score: 
18.045, Residue No: 10) is found to bind total 31 MHC alleles. Although it 
showed an antigenicity score of 0.8605, because of its high IC50 value for 
DRB1*0101 (216.77 nM), it may not be considered as a good vaccine 
candidate. Another epitope “LNKLASQDW” from comL Cluster-III 
(Score: 10.899, Residue. No: 10) that binds total 18 MHC molecules has    
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antigenicity and IC50 scores 0.7699 and 36.39 nM, respectively. Therefore, 
this epitope is a better option than the previous one. The third epitope 
“DELNSSNYT” from comL cluster-I is found to bind total 11 MHC 
molecules but does not interact with any MHC-II alleles as per the Propred 
analysis. But the epitope has antigenic and IC50 (DRB1*0101) scores 
1.0744 and 52.84 nM, respectively. Therefore, it is evident that epitope 
prediction differs according to different algorithms and the epitope 
“DELNSSNYT” may not be a good candidate for use as vaccine (Table 4 
see supplementary material). Based on the second level screening, it has 
been found that  epitope sequence “LNKLASQDW” can probably interact 
with all the HLA alleles (>1000) and specifically binds to our selected 
HLA molecules (A*0201, A*0204, B*2705, DRB1*0101, and 
DRB1*0401) with acceptable scores based on T-Epitope Designer,   
MHCPreds, and VaxiJen analysis (Tables 4, 5, and 6 see supplementary 
material). Therefore this “LNKLASQDW” epitope is finally selected from 
comL.  
 
Three epitopes from pilV are selected based on antigenic scores and IC50 
values at screening-I. Epitopes “TCTVTLNDG” and “ETCTVTLND” of 
cluster-II (Score: 24.626, Residue. No: 13) showed antigenic scores 0.8669 
and 1.1813, respectively. However, similar to the comL “DELNSSNYT” 
epitope, these two epitopes do not interact with any MHC-II alleles as per 
the Propred analysis but have IC50 values 5.66nM and 40.64nM, 
respectively for DRB1*0101 as analyzed with MHCpred. Therefore, these 
two epitopes may not be considered as vaccine candidates based on the 
same ground similar to comL. The third epitope “FEKYDSTKL” in 
cluster-I (Score: 43.692, Residue No: 17) is found to bind total 25 MHC 
molecules comprising of both the classes. The epitope has antigenicity and 
IC50 values 0.8655 and 8.73, respectively. Therefore, this epitope can be 
considered as best epitope among all epitopes derived form pilV (Table 4 
see supplementary material). Results from the second level screening 
(Tables 5 and 6 see supplementary material) also support its usefulness 
to be potential peptide vaccine.  
 
Although the full-length protein is non-antigenic, one epitope 
“WDLYLKSLS” from cysW Cluster-I (Score: 46.051, Residue No: 13) is 
found antigenic (VaxiJen score: 1.3624) and can bind total 20 MHC 
molecules comprising of both the MHC classes. The IC50 value of this 
epitope for DRB1*0101 is 11.69 nM which indicates good inhibition of a 
given biological process by half (Table 4 see supplementary material). 
The epitope has also been found to bind selected MHC molecules 
(A*0201, A*0204, B*2705, and DRB1*0401) and more than 80% HLA 
molecules selected for second level T-epitope screening in this study 
(Tables 5 and 6 see supplementary material). Therefore this epitope can 
be considered for vaccine development.  
  
Among the identified epitopes from ddl, “YGEDGAVQG” of cluster-III 
having VaxiJen and IC50 scores 2.6304 and 20.18, respectively binds total 
20 MHC alleles comprising of both the classes. This epitope is found to be 
best epitope having highest antigenicity among all epitopes identified from 
four proteins under study. Another epitope “YAFDPKETP” from ddl is 
also found suitable that has antigenicity and IC50 scores 0.6362 and 51.29 
nM, respectively. This epitope is located in cluster-I (Score: 12.871, 
Residue No: 9) and interacts with 13 MHC class-I and 8 MHC class-II 
alleles (Table 4 see supplementary material). However, in the second 
screening, “YGEDGAVQG” peptide fails to bind A*0201, and A*0204 
with positive scores (Table 6 see supplementary material) and is also 
capable to bind only 70% HLA molecules (Table 5 see supplementary 
material) based on T-Epitope Designer analysis. Therefore this epitope 
may not be suitable for designing a vaccine against the pathogen. 
 
Conclusion: 
In this study, by using computational approaches based on sequence, 
structure, QSAR, simulation, and fold level analysis, we identified four 
potential T-epitopes derived from antigenic B-cell epitopes of four exo-
membrane essential proteins of N. gonorrhoeae.  Selected T-epitopes 
[“LNKLASQDW” from ComL., “FEKYDSTKL” from pilV, 
“WDLYLKSLS” from cysW, and “YAFDPKETP” from ddl] are antigenic 
and have much potential to interact with most common human HLA alleles 
(A*0201, A*0204, B*2705, DRB1*0101, and DRB1*0401). These 
epitopes are also found to interact with >75% of HLA molecules in a 
binding screening using T-Epitope Designer (that contains >1000 HLA 
molecules). Therefore these selected epitopes are likely to induce both the 
B-cell and T-cell mediated immune responses. Homology and simulation 
results also support the suitability of these epitopes as vaccine candidates. 
However, there are several pitfalls in developing a good vaccine and 
moreover there is lack of proper experimental disease model for 
gonorrhea; suitable animal model should be used for experimental 
validation of these epitopes to confirm these in silico results. 
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Supplementary material: 
 
Table 1: Reported T-cell epitopes in Neisseria gonorrhoeae. 
Proteins   Epitope Sequence  Amino acid positions  MHC Binding  Reference 
Lactoferrin receptor precursor ASADKPYSY  496-504 HLA-A*0101  [40] 
FDEKNQDKY 567-575  HLA-A*0101  [40] 
IRDMTEKQY 374-382  HLA-A*0101  [40] 
LTEIDIRDY 751-759  HLA-A*0101  [40] 
RLDAFRQTY 248-256  HLA-A*0101  [40] 
 
RPDLSLRSY 806-814  HLA-A*0101  [40] 
Carbamoyl-phosphate synthase large chain  DPEMADVTY  57-65  HLA-A*0101  [40] 
HSAEALQKY 723-731  HLA-A*0101  [40]   
EKEVVPDFY 874-882  HLA-A*0101  [40] 
IgA-specific serine endopeptidase precursor GKDLYYKNY  581-589  HLA-A*0101  [40] 
GTYDYWAGY 296-304  HLA-A*0101  [40] 
YDEDDYSYY 563-571  HLA-A*0101  [40] 
KAEVHTFYY 103-111  HLA-A*0101  [40] 
KSWQEWNIY 307-315  HLA-A*0101  [40] 
LSGNGHFHY 884-892  HLA-A*0101  [40] 
LSQDALTNY 264-272  HLA-A*0101  [40] 
LTAGLDFAY 1442-1450  HLA-A*0101  [40] 
NTFVQANLY 1347-1355  HLA-A*0101  [40] 
QNDYDEDDY 560-568  HLA-A*0101  [40] 
 
LRDLSQAYRY 215-224  Mamu-B*17  [40] 
PilC2 GTATYLPPY  105-113  HLA-A*0101  [40] 
KTQNGKKQY 493-501  HLA-A*0101  [40] 
QRESTAMAY 252-260  HLA-A*0101  [40] 
RSYNLKLSY 555-563  HLA-A*0101  [40] 
 
TTRPGLAGY 136-144  HLA-A*0101  [40] 
DNA gyrase subunit A  VREFPEDQY  648-656  HLA-A*0101  [40] 
 VREFPEDQY  648-656  Mamu-B*17  [41] 
Pilus-associated protein  QRESTAMAY  253-261  Mamu-B*17  [41] 
 QRESTAMAYY  253-262  Mamu-B*17  [41] 
50S ribosomal protein L6  GSDKQVVGQ 135-143  HLA-A*0101, HLA-A*0201,  
HLA-A*0301, HLA-A*1101,  
HLA-A*2403,HLA-A*2601, 
HLA-A*3101,HLA-A*6901, 
HLA-B*0702,HLA-B*0801, 
HLA-B*1501,HLA-B*2705 
HLA-B*4001,HLA-B*5801 
HLA-B*4402 
[41] 
 
 
 
Table-2: B-cell epitopes from full length proteins using BCPred (BCPred +AAP). Antigenicity of full length proteins as-well-as all B-cell epitopes 
derived from each protein was calculated using VaxiJen. TMHMM based surface exposed amino acid sequence of the proteins are given. Selected B-cell 
epitopes are in bold letters. 
Name of protein/  
VaxiJen scores 
BCPred  epitope sequences  Amino  acid 
Positions  
BCPred scores   VaxiJen  scores 
for B-cell 
epitopes 
TMHMM based 
surface exposed 
amino acid sequence 
BCPred Predictions 
KSKGIDAYAFDPKETPLSEL 33    0.961  0.8035 
NGKGLPGIHIIPATEFYDYE 189    0.938  0.2560 
DDTIYQCPSEDLTEAEESLM 214    0.893  -0.1183 
LPVPEFAVLYDDTDFDAVEE 111    0.878  0.4969 
QTAFNILHGTYGEDGAVQGA 58    0.839  1.0836 
KVKEKGRLKSVYEELKHLQG 151    0.834  0.2792 
 
D-alanine--D-
alanine ligase 
(ddl) 
 
 
VaxiJen score:   
0.5155  AAP Predictions 
 
 
 
 
 
 
1  –– 304    
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VLNGKGLPGIHIIPATEFYD 187    1  0.4356 
GLPVPEFAVLYDDTDFDAVE 110    1  0.6695 
YGEDGAVQGALELLGIPYTG 68    1  0.7979 
LLEINTLPGMTGHSLVPKSA 264    1  0.7017 
NALKSKGIDAYAFDPKETPL 30    1  0.9018 
BCPred Predictions 
MKPYSANPNLTEPRRLRMLL 1    0.892  0.6722 
AAREIIPLMQTQGDSEEQAA 159    0.815  0.6665 
AAP Predictions 
GAVSVVSGHIRGETNTIPLL 217    1  0.8433 
FLGKQLLTTLLDLPFSVSPV 94    1  0.4710 
TQGDSEEQAALVLGASGWQM 169    1  0.9722 
WSAVKLTLITALIVVPVNAV 61    1  0.5057 
 
Sulfate transport 
permease protein 
C (cysW )  
 
VaxiJen score: 
0.6091 
 
FYEALKGGWDLYLKSLSDPE 40    0.056  0.6316 
  
 
 
42  ––   66 
 
129  ––   137 
 
BCPred Predictions 
ANRAKKIIGSYQNTRYVEES 198    0.979  -0.0246 
VEKLYAEAQDELNSSNYTRA  35   0.936 0.5865 
RFRRLHPQHPNMDYALYLRG 97    0.825  0.7576 
QSQLDTAYAYYKDDEKDKAL 73    0.763  0.3129 
AAP Predictions 
LETNFPKSPFLTHAWQPDDM 241    1  0.1626 
LNKLASQDWSDRDPKANREA  127   1 0.9646 
EKLYAEAQDELNSSNYTRAV 36    1  0.5626 
 
 
Competence 
lipoprotein 
(comL) 
 
 
VaxiJen score: 
0.3968 
RQSQLDTAYAYYKDDEKDKA 72    0.955  0.4956 
 
 
 
 
 
1  ––  267 
BCPred Predictions 
QAAPDTATNEGETCTVTLND 93    0.987  1.4611 
QNLERYYRQKGTFEKYDSTK 52    0.866  0.1548 
AAP Predictions 
APDTATNEGETCTVTLNDGG  95   1 1.4930 
 
Type IV pilin 
protein (pilV)  
 
VaxiJen score: 
0.5312 
 
YYRQKGTFEKYDSTKLKQNK  57   1 0.5050 
 
 
30  ––  129 
 
Table-3: Selected B-cell epitopes using both the modules of BCPreds (BCPred +AAP), TMHMM based topology, and antigenicity using VaxiJen.  
Protein  name  SL No. of  B-cell 
epitopes 
Amino acid 
position of epitope 
BCPred  epitope sequence  BCPred scores  VaxiJen 
scores 
1 58  QTAFNILHGTYGEDGAVQGA  0.839  1.0836  ddl 
 2  30  NALKSKGIDAYAFDPKETPL  1  0.9018 
cysW  1 40  FYEALKGGWDLYLKSLSDPE  0.056  0.6316 
1 35  VEKLYAEAQDELNSSNYTRA  0.936  0.5865  comL 
2 127  LNKLASQDWSDRDPKANREA  1 0.9646 
1 95  APDTATNEGETCTVTLNDGG  1 1.4930  pilV 
2 57  YYRQKGTFEKYDSTKLKQNK  1 0.5050 
 
 
 
Table-4:  Common epitopes from each protein that can produce both the B- and T-cell mediated immunity are representes along with their various 
parameters. Epitopes selected as vaccine candidates are highlight in bold letters. 
Proteins 
and 
Uniprot 
ID 
 
SL No. 
of  B-cell 
epitopes 
Predicted 
epitopes 
(Propreds + 
MHCPred) 
Vacxigen 
score 
Amino 
acid 
position 
IC50 value of 
epitopes  for 
DRB1*0101 
(MHCPred) 
Number of 
MHC Class 
I binding 
alleles 
(Propred1) 
Number of 
MHC Class 
II binding 
alleles 
(Propred) 
Total 
number 
of MHC 
binding 
alleles 
Cluster scores 
(Pepitope) 
1  YGEDGAVQG 
FNILHGTYG  
 
 
2.6304 
0.3382 
68 
61 
20.18 
323.59 
17 
0 
3 
25 
20 
25 
 
 
ddl 
 
Q5F6M0 
 
2  YAFDPKETP 0.6362  40  51.29  13 
 
8 
 
21 
Cluster-I 
Score: 
12.871/Res. No: 
9 
YAFDPKETP 
Cluster-II 
Score: 
8.4077/Res. No: 
8 
FNILHGTYG 
Cluster-III 
Score: 
7.483/Res. No:9 
YGEDGAVQG 
cysW 
 
Q5F9F0 
 
1 LYLKSLSDP 
WDLYLKSLS 
YLKSLSDPE 
 
-0.6286 
1.3624 
-0.5090 
50 
48 
51 
15.56 
11.69 
1.05 
24 
2 
33 
18 
18 
7 
42 
20 
40 
Cluster-I 
Score: 
46.051/Res. 
No:13    
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  LYLKSLSDP 
WDLYLKSLS 
YLKSLSDPE 
1  LNSSNYTRA 
VEKLYAEAQ  
DELNSSNYT 
 
 
 
0.8605 
0.0915 
1.0744 
46 
35 
44 
216.77 
156.31 
52.48 
27 
0 
11 
4 
11 
0 
31 
11 
11 
 
ComL 
 
 
Q5F9W0 
2 LASQDWSDR 
LNKLASQDW  
 
 
0.1974 
0.7699 
130 
127 
21.68 
36.39 
 
8 
5 
0 
13 
8 
18 
Cluster-I 
Score: 18.045/ 
Res. No: 10 
LNSSNYTRA 
DELNSSNYT 
Cluster-II 
Score: 11.057/ 
Res. No: 9 
LNKLASQDW  
Cluster-III 
Score: 10.899/ 
Res. No: 10 
LASQDWSDR 
1  TCTVTLNDG 
ETCTVTLND 
0.8669 
1.1813 
105 
104 
5.66 
40.64 
15 
10 
0 
0 
15 
10 
 
 
pilV  
 
 
Q5F6V4 
  2 YYRQKGTFE 
FEKYDSTKL 
YRQKGTFEK 
0.1821 
0.8655 
0.1519 
57 
64 
58 
 
 
 
12.19 
8.73 
175.79 
4 
15 
7 
5 
10 
43 
9 
25 
50 
Cluster-I 
Score: 43.692/ 
Res. No: 17 
YYRQKGTFE 
FEKYDSTKL 
YRQKGTFEK 
Cluster-II  
Score: 24.626/ 
Res. No: 13 
TCTVTLNDG 
ETCTVTLND 
 
Table-5: Screening of T-epitopes using T-epitope Designer.  
Proteins Epitopes T-Epitope  Designer 
(NO of binders) 
Comments  Lowest score  Highest score 
YAFDPKETP  99.99%  Almost all alleles  A*2434 [424.64]  A*2607 [2570.92]  ddl 
YGEDGAVQG  70%    Mostly positive for 
almost all B* & C* 
A*0234 [41.45]  B*4003 [979.16] 
cysW  WDLYLKSLS  80%    Mostly  positive  for 
almost all B* & C* 
A*0221 [10.19]  C*0705  [2197.53] 
ComL LNKLASQDW    100%  All alleles  A*0101 [236.75]  C*1802 [2340.96]  
pilV   FEKYDSTKL  100%  All alleles  A*3306  [170.86]  C*1801 [3465.96] 
 
Table-6: Final selection of T-epitopes from four N. gonorrhoeae proteins 
T-Epitope Designer  MHCPred (IC50 Value)  Proteins  Epitopes 
A*0201 A*0204 B*2705 DRB1*0101  DRB1*0401 
YAFDPKETP  1866.30 1464.79 2261.31 51.29  592.93  ddl 
YGEDGAVQG -103.79  -309.46 714.11  20.18  690.24 
cysW  WDLYLKSLS  758.14 641.45 1401.35  11.69  223.36 
ComL LNKLASQDW    788.83 508.12 1189.16  36.39  959.40 
pilV   FEKYDSTKL  714.75 248.08 1597.48  8.73  462.38 
 
Table-7: Homology modeling of selected proteins using Phyre.  Selected template, E-values, fold descriptor, and super family for each protein are given. 
Proteins  SCOP Code/ Protein 
PDB ID 
E-value Fold/PDB  descriptor  Super  family 
Q5F6M0 
ddl 
c1iowA_ 2.1e-32  Ligase  d-ala:d-ala  ligase 
Q5F9F0 
cysW  
c2onkI_ 4.7e-27  Mmembrane  protein   Molybdate/tungstate 
abc transporter 
permease 
Q5F9W0 
ComL 
c2q7fB_  4.2e-31  Protein binding  yrrb protein 
Q5F6V4  
pilV 
d2pila_  2.4e-11  Pili  subunits  Type IV Pilin Pak 
from Pseudomonas 
aeruginosa 
 
 
 
 
 
 
 